Loading
JUR-003 is an experimental biologic from Juri Biosciences, in phase 1 trials for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer.
JUR-003 is a biologic (T-cell engager per OnCo text; registry says only 'Biological') from Juri Biosciences, with EpimAb Biotherapeutics as partner. A biologic given intravenously in a first-in-human phase 1a/1b study in prostate cancer. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1a/1b NCT07824349 recruiting (registry, first posted 17 Sep 2026). Whether it works in people has not been established unless a trial below reports it.
A biologic given intravenously in a first-in-human phase 1a/1b study in prostate cancer.
1.One arm of JUR-003 binds its target on the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JUR-003" OR ABSTRACT:"JUR-003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JUR-003, not a curated reading list.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/